Spotlight
Clinical
Articles
CME/CE
Oculus imaging device approved by FDA
The PARK 1 (Pachymeter/Autorefractor/Keratometer) imaging device (Oculus) has received premarket approval from the FDA.
The PARK 1 (Pachymeter/Autorefractor/Keratometer) imaging device (Oculus) has received premarket approval from the FDA.
The slim, ergonomically-designed device features a 5.7" LCD display, and comprises an autorefractor combined with a Scheimpflug based non-contact pachymeter, to photograph and measure corneal thickness and lens refractive power. It can be set to PARK, ARK or P measurement modes.
The PARK 1 will be launched officially at this year's American Academy of Ophthalmology (AAO) meeting, which is to be held on November 8–11 in Atlanta, GA, US.
Related Videos
Related Content
